SGIOY:OTO-Shionogi & Co. Ltd. ADR (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic | OTC Pink

Last Closing

USD 9.545

Change

0.00 (0.00)%

Market Cap

USD 16.23B

Volume

0.41M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Shionogi & Co Ltd manufactures and distributes pharmaceuticals, diagnostic reagents and medical devices.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-15 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MKGAF MERCK Kommanditgesellschaft au..

+4.15 (+2.38%)

USD 79.35B
MKKGY Merck KGaA ADR

-2.48 (-6.92%)

USD 78.81B
TKPHF Takeda Pharmaceutical Co. Ltd.

+0.91 (+3.64%)

USD 40.01B
HLNCF Haleon plc

+0.14 (+3.28%)

USD 38.24B
TEVJF Teva Pharmaceutical Industries..

N/A

USD 19.53B
HNSPF Hansoh Pharmaceutical Group Co..

N/A

USD 13.33B
SGIOF Shionogi & Co. Ltd

N/A

USD 12.44B
IPSEY Ipsen SA ADR

+0.41 (+1.34%)

USD 11.45B
ESAIY Eisai Co. Ltd.

+0.24 (+2.43%)

USD 11.44B
ESALF Eisai Co. Ltd

+1.60 (+4.17%)

USD 11.40B

ETFs Containing SGIOY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -20.27% 40% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.27% 41% F 27% F
Trailing 12 Months  
Capital Gain -13.62% 62% D 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.62% 61% D- 45% F
Trailing 5 Years  
Capital Gain -31.48% 78% C+ 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.48% 78% C+ 45% F
Average Annual (5 Year Horizon)  
Capital Gain -3.56% 52% F 32% F
Dividend Return -3.56% 51% F 28% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 17.79% 98% N/A 89% A-
Risk Adjusted Return -20.03% 43% F 25% F
Market Capitalization 16.23B 99% N/A 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.